Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(146 productos)
- Bcr-Abl(102 productos)
- EGFR(572 productos)
- FAK(72 productos)
- FLT(92 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(245 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(79 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(268 productos)
Mostrar 6 subcategorías más
Se han encontrado 1431 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78MLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Fórmula:C20H16F6N4O2SForma y color:SolidPeso molecular:490.422Apoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Fórmula:C23H21ClN8O2S2Forma y color:SolidPeso molecular:541.048MET/PDGFRA-IN-2
<p>MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positive</p>Fórmula:C29H29N7OPureza:98%Forma y color:SolidPeso molecular:491.59hCA/VEGFR-2-IN-2
<p>Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII and</p>Fórmula:C23H26N6O5SPureza:98%Forma y color:SolidPeso molecular:498.55Syk-IN-4
<p>Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.</p>Forma y color:SolidAD57 (hydrochloride)
CAS:<p>AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.</p>Fórmula:C22H21ClF3N7OPureza:98%Forma y color:SolidPeso molecular:491.9K882
<p>K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.</p>Fórmula:C18H16N2O2Forma y color:SolidPeso molecular:292.33BMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Fórmula:C27H29Cl2FN8O3Pureza:99.11%Forma y color:Odour SolidPeso molecular:603.47JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.401IOX2-NH2-Methyl
<p>IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.</p>Fórmula:C20H19N3O5Pureza:97.64% - 99.31%Forma y color:SolidPeso molecular:381.39Trastuzumab envedotin
<p>Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.</p>Forma y color:Odour LiquidPTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Fórmula:C49H51N11O8Pureza:98%Forma y color:SolidPeso molecular:922SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SForma y color:SolidPeso molecular:818.95EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PForma y color:SolidPeso molecular:805.72Angiogenesis related Compound Library
<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>Forma y color:Odour SolidFGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Fórmula:C28H26Cl2N4O3Forma y color:SolidPeso molecular:537.44SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Fórmula:C68H84N12O9Pureza:98%Forma y color:SolidPeso molecular:1213.47Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Forma y color:Odour SolidAbl Cytosolic Substrate
CAS:<p>Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).</p>Fórmula:C64H101N15O16Pureza:98%Forma y color:SolidPeso molecular:1336.58KIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Fórmula:C26H18F3N5O2Forma y color:SolidPeso molecular:489.449PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Fórmula:C46H48N10O6Forma y color:SolidPeso molecular:836.94TL13-112
CAS:<p>TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).</p>Fórmula:C49H60ClN9O10SPureza:98%Forma y color:SolidPeso molecular:1002.57HIF-1 inhibitor-4
CAS:<p>HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM.</p>Fórmula:C18H19IN2O2Pureza:99.26%Forma y color:SolidPeso molecular:422.26INCB-000928
CAS:<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Fórmula:C30H38N4O3Pureza:98.93%Forma y color:SolidPeso molecular:502.65SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Fórmula:C25H29F3N4O3Forma y color:SolidPeso molecular:490.52HIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Forma y color:Odour SolidAG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Forma y color:SolidPeso molecular:352.21PACAP-38 (31-38), human, mouse, rat
CAS:<p>PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production</p>Fórmula:C47H83N17O11Pureza:98%Forma y color:SolidPeso molecular:1062.27Sorafenib-d4
CAS:<p>Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.</p>Fórmula:C21H16ClF3N4O3Pureza:98%Forma y color:SolidPeso molecular:468.85VEGFR2/HDAC1-IN-1
<p>VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.</p>Pureza:98%Forma y color:Odour SolidPROTAC FLT-3 degrader 1
CAS:<p>PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.</p>Fórmula:C52H61N9O9S2Pureza:98%Forma y color:SolidPeso molecular:1020.23cep-5214
CAS:<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Fórmula:C28H28N2O3Forma y color:SolidPeso molecular:440.53Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SForma y color:SolidPeso molecular:442.51PROTAC EGFR degrader 4
CAS:<p>PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).</p>Fórmula:C55H70N12O4SForma y color:SolidPeso molecular:995.29DB1113
CAS:<p>DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.</p>Fórmula:C59H68F3N13O6SForma y color:SolidPeso molecular:1144.31Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Fórmula:C19H15N5O2SForma y color:SolidPeso molecular:377.42SNIPER(ABL)-033
CAS:<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Fórmula:C61H73F3N10O9S2Pureza:98%Forma y color:SolidPeso molecular:1211.42AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Fórmula:C17H14N6Pureza:99.88%Forma y color:SolidPeso molecular:302.33ALK-IN-9
CAS:<p>ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.</p>Fórmula:C20H21FN6O3Forma y color:SolidPeso molecular:412.425(R)-3-Hydroxy Midostaurin
CAS:<p>(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.</p>Fórmula:C35H30N4O5Pureza:98%Forma y color:SolidPeso molecular:586.648PROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Fórmula:C43H40N10O6Pureza:98%Forma y color:SolidPeso molecular:792.84BTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Fórmula:C23H32N4O5Forma y color:SolidPeso molecular:444.532HDS 029
CAS:<p>HDS 029 has a wide range of applications in life science related research.</p>Fórmula:C17H11ClFN5OForma y color:SolidPeso molecular:355.76SNIPER(ABL)-015
<p>SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5</p>Fórmula:C58H70F3N9O9Pureza:98%Forma y color:SolidPeso molecular:1094.23CPD-1224
CAS:<p>CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.</p>Fórmula:C43H47ClN8O7SForma y color:SolidPeso molecular:855.4TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Forma y color:SolidPeso molecular:404.16485JAK/HDAC-IN-2
<p>JAK/HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1/2 and HDAC3/6 at nanomolar concentrations.</p>Fórmula:C28H38N6O5SPureza:98%Forma y color:SolidPeso molecular:570.7
